Evaluation of TP53 and HER-2/neu Genes Expression Levels in Gestational Trophoblastic Diseases Cases and Determining Their Predictive Value in Diagnosis of Malignancy and Disease Progression

Background: Gestational trophoblastic disease (GTD) is a general term that includes several types of pathologically different diseases, which range from hydatidiform mole to choriocarcinoma. Early differentiation of these types is important to determine treatment strategy and prognosis. Objectives: Genetic markers such as TP53 and HER-2/neu expression are recently shown to have diagnostic and prognostic values. The aim of this study was to evaluate its significance. Methods: We enrolled 62 patients diagnosed with GTD referred to Imam Hossein Hospital in Tehran, Iran between 2012 and 2017. Endometrial pathologic specimens were stained, using the immunohistochemistry (IHC) method for the expression of TP53 and HER-2/neu genes. Expression levels determined by IHC were compared between final pathologic diagnoses, using one-way ANOVA test (analysis of variances), which detects significant differences between the means of 3 or more independent groups. Results: Out of 62 participants, 32 and 24 cases were diagnosed as partial and complete hydatidiform mole, respectively. Four cases had invasive hydatidiform mole and only 2 cases were diagnosed as choriocarcinoma. Analysis using ANOVA demonstrated that expression levels of both TP53 and HER-2/neu genes are significantly higher among patients with invasive form and choriocarcinoma compared with non-invasive hydatidiform mole (P < 0.05 for both genes). The receiver operating characteristic (ROC) curve for each gene showed that more than 55% positive staining for the TP53 gene can differentiate non-invasive hydatidiform mole from invasive form and choriocarcinoma with 100% sensitivity, and 92.9% specificity. Conclusions: TP53 expression might serve as a potential diagnostic aid to differentiate benign and malignant GTDs and a future target for adjusting treatment based on the expression levels.

[1]  M. Mokni,et al.  Immunohistochemical analysis of c-erbB-2, Bcl-2, p53, p21WAF1/Cip1, p63 and Ki-67 expression in hydatidiform moles. , 2019, Pathology, research and practice.

[2]  R. Berkowitz,et al.  Update on the diagnosis and management of gestational trophoblastic disease , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[3]  Tenya Abdulhameed,et al.  Immunoexpression of P53 protein in trophoblastic diseases , 2017 .

[4]  Qibin Wu,et al.  Expression patterns of maspin and mutant p53 are associated with the development of gestational trophoblastic neoplasia , 2016, Oncology letters.

[5]  M. Hasanzadeh,et al.  Immunohistochemistry Study of P53 and C-erbB-2 Expression in Trophoblastic Tissue and Their Predictive Values in Diagnosing Malignant Progression of Simple Molar Pregnancy , 2016, Iranian Journal of Cancer Prevention.

[6]  N. Sebire,et al.  Management and survival of patients with FIGO high-risk gestational trophoblastic neoplasia: the U.K. experience, 1995-2010. , 2014, The Journal of reproductive medicine.

[7]  S. T. Fayed,et al.  The predictive value of C-erbB-2 and p53 overexpression in the management of molar pregnancy , 2012 .

[8]  Yi-qun Gu,et al.  [Immunohistochemistry of p57 and p53 protein in differential diagnosis of hydropic abortion, partial and complete hydatidiform mole]. , 2011, Zhonghua bing li xue za zhi = Chinese journal of pathology.

[9]  R. Berkowitz,et al.  Current management of gestational trophoblastic diseases. , 2009, Gynecologic oncology.

[10]  P. Clement,et al.  Trophoblastic Lesions, Miscellaneous Primary Uterine Neoplasms, Hematopoietic Neoplasms, and Metastatic Neoplasms to the Uterus , 2008 .

[11]  Manuel Serrano,et al.  p53: Guardian of the Genome and Policeman of the Oncogenes , 2007, Cell cycle.

[12]  A. Golan,et al.  Assessment of Her-2/neu expression in hydatidiform moles for prediction of subsequent gestational trophoblastic neoplasia. , 2007, Gynecologic oncology.

[13]  M. Vogel,et al.  Diagnostic aspects of hydatidiform mole with persistence of polymorphic trophoblastic hyperplasia. , 2003, Anticancer Research.

[14]  P. Lorigan,et al.  Characteristics of women with recurrent molar pregnancies. , 2000, Gynecologic oncology.

[15]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[16]  D. Grimes,et al.  Epidemiology of hydatidiform mole during early gestation. , 1986, American journal of obstetrics and gynecology.